Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy

Objectives: Second-line therapy for relapsed or refractory acute myeloid leukemia (R/R AML) involves either intensive chemotherapy (ICT) or azacitidine and venetoclax (AZAVEN), but their comparative infectious risks are not well established. Methods: This retrospective multicenter study evaluated in...

詳細記述

書誌詳細

主要な著者:	Maxime Bobo, Lucas Lefevre, Paul Mallet-Guy, Aurelia Chacon, Martin Eloit, Patrice Chevallier, Pierre Peterlin, Jean-Baptiste Mear, Tony Marchand, Maria-Pilar Gallego-Hernanz, Chama Mokeddem, Emmanuel Gyan, Aline Tanguy-Schmidt, Nicolas Vallet
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2026-03-01
シリーズ:	International Journal of Infectious Diseases
主題:	AML Hypomethylating agent Venetoclax Intensive chemotherapy Infection Febrile neutropenia
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S1201971226000470
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!